Biopharma Credit Plc

Biopharma Credit (BPCR)

Trade Now

Capital at risk Advertisement
Company name:Biopharma Credit Plc
EPIC:BPCRTrading Currency:USD
Market Sector:ON15ISIN:GB00BDGKMY29
Market Segment:SET3Share Type:DE
WWW Address:Description:ORD USD0.01
Industry Sector:UNKNOWN
 Price Price Change [%] Bid Offer Open High Low Volume
 0.96 0.0 [0.00] 0.95 0.96 0.96 0.96 0.96 440,790
 Market Cap. [m] Shares In Issue [m] Beta EPS DPS PE Ratio Yield 52-Wks-Range
 1,318.92 1,373.87 0.00 5.80 - 16.55 - 1.05 - 0.92

Biopharma Credit Key Figures

(at previous day's close)
Market Cap.1,318.92m
Shares In Issue1,373.87m
Prev. Close0.96
PE Ratio16.55 
Dividend Yield-%
EPS - basic5.80¢($)
Dividend PS-¢($)
Dividend Cover- 
Cash Flow PS4.23¢($)
Return On Equity (ROE)5.78%
Operating Margin80.10%
PEG Factor-0.55 
EPS Growth Rate-29.95%
Dividends PS Growth Rate-%
Net Debt-183.88m
Gross Gearing0.68%
Quick Assets193.48m
Net Working Capital184.08m
Intangibles / Fixed Assets-%
Turnover PS7.24¢($)
Pre-Tax Profit PS5.80¢($)
Retained Profit PS-2.49¢($)
Cash PS14.07¢($)
Net Cash PS13.38¢($)
Net Tangible Asset Value PS *100.37¢($)
Net Asset Value PS100.37¢($)
Spread0.01 (0.63%) 

Biopharma Credit Balance Sheet


Share Price Performance

Sample Period HighLow
1 week0.970.95
4 weeks0.970.93
12 weeks0.980.93
1 year1.050.92

Share Price Chart (5 years)

Biopharma Credit Historic Returns

Period OpenChange%Open Avg.Avg. Daily Vol [m]Total Vol [m]VWAP
1 week0.950.011.050.954.540.96
4 weeks0.960.000.210.932.420.95
12 weeks0.950.011.270.931.960.96
26 weeks1.03-0.07-6.800.922.270.97
1 year0.99-0.03-2.640.922.040.98
3 years1.02-0.06-5.880.851.470.98
5 years1.11-0.15-13.510.851.100.99

Biopharma Credit Key Management Ratios

Biopharma Credit Investment Ratios

(Market value analysis) at previous day's close
PQ Ratio0.15 
PE Ratio16.55 
Tobin's Q Ratio 0.94 
Tobin's Q Ratio (excl. intangibles)0.94 
Dividend Yield-%
Market-to-Book Ratio0.96 
Price-to-Pre-Tax Profit PS16.55 
Price-to-Retained Profit PS-38.54 
Price-to-Cash Flow PS22.71 
Price-to-Sales PS13.26 
Price-to-Net Tangible Asset Value PS0.96 
Price-to-Cash PS6.82 
Net Working Capital PS13.40 
Price Pct to Working Capital PS7.16%
Earnings Yield6.04%
Average PE0.18 
Years in average4 
PE to PE average9,277.99%

Biopharma Credit Financial Ratios

(Leverage Ratios)
Debt Ratio-%
Debt-to-Equity Ratio- 
Debt-to-Equity Ratio (excl. Intgbl)- 
Debt-to-Equity Market Value- 
Net Gearing-13.24%
Net Gearing (excl. Intangibles)-13.24%
Gross Gearing0.68%
Gross Gearing (excl. Intangibles)0.68%
Gearing Under 1 Year0.68%
Gearing Under 1 Year (excl. Intgbl)0.68%
(Liquidity Ratios)
Net Working Capital to Total Assets13.26%
Current Ratio20.60 
Quick Ratio (Acid Test)20.60 
Liquidity Ratio20.58 
Cash & Equiv/Current Assets99.89%
(Solvency Ratios)
Enterprise Value1,125.65m
CFO/Attributable Profit0.73 
Total Debt/Equity Market Value0.01 
Total Debt/Sales0.09 
Total Debt/Pre-Tax Profit0.12 
Total Debt9.39m
Total Debt/Net Current Assets0.05%
(Dodds - Graham Ratios)
3 yr Compound Earnings Growth-%
5 yr Compound Earnings Growth-%
10 yr Compound Earnings Growth-%
Earn drops > 5% in 10yrs1 
Beta (60-Mnth)Beta (36-Mnth)

Biopharma Credit Operating Ratios

(Profitability Ratios)
Return On Capital Employed (ROCE)5.78%
Return On Assets (ROA)5.66%
Net Profit Margin80.10%
Assets Turnover0.07 
Return On Equity (ROE)5.78%
Return On Investment (ROI)5.72%
Dividend Payout Ratio-%
Plowback Ratio100.00%
Growth from Plowback Ratio5.73%
Net Income Of Revenues-34.40%
(Asset Utilisation Multiples)
Shareholders Equity Turnover0.07 
Fixed Assets Turnover0.09 
Current Assets Turnover0.39 
Net Working Capital Turnover 
Inventory Turnover- 
(Other Operating Ratios)
Total Assets-to-Sales14.16 
Debt Collection Period30.11Days

Biopharma Credit Dividends

Announcement DateTypeCurr.Dividend AmountPeriod StartPeriod EndEx DateRecord DatePayment DateTotal Dividend Amount
16 Aug 2022InterimUSX1.7502/03/202230/06/202225/08/202226/08/202223/09/2022-
27 Apr 2022InterimUSX1.7531/03/202131/03/202205/05/202206/05/202231/05/20227.00
24 Feb 2022InterimUSX1.7531/08/202131/12/202103/03/202204/03/202231/03/2022-
04 Nov 2021InterimUSX1.7530/03/202130/09/202118/11/202119/11/202117/12/2021-
12 Aug 2021InterimUSX1.7502/03/202130/06/202119/08/202120/08/202117/09/2021-
26 May 2021InterimUSX1.7531/03/202031/03/202119/08/202120/08/202117/09/20217.29
11 Mar 2021InterimUSX2.0431/08/202031/12/202018/03/202119/03/202116/04/2021-
12 Nov 2020InterimUSX1.7530/03/202030/09/202019/11/202020/11/202018/12/2020-
12 Aug 2020InterimUSX1.7501/03/202030/06/202020/08/202021/08/202018/09/2020-
14 May 2020InterimUSX1.7531/03/201931/03/202021/05/202022/05/202019/06/20208.28
20 Feb 2020InterimUSX3.0331/08/201931/12/201927/02/202028/02/202027/03/2020-
07 Nov 2019InterimUSX1.7530/03/201930/09/201914/11/201915/11/201917/12/2019-
07 Aug 2019InterimUSX1.7502/03/201930/06/201915/08/201916/08/201920/09/2019-
14 May 2019InterimUSX1.7531/03/201831/03/201923/05/201924/05/201921/06/20197.18
21 Feb 2019InterimUSX1.9331/08/201831/12/201828/02/201901/03/201929/03/2019-
22 Oct 2018InterimUSX1.7530/03/201830/09/201801/11/201802/11/201830/11/2018-
16 Aug 2018InterimUSX1.7502/03/201830/06/201830/08/201831/08/201828/09/2018-
24 May 2018InterimUSX1.3431/03/201731/03/201831/05/201801/06/201829/06/20185.44
01 Mar 2018InterimUSX2.1031/08/201731/12/201708/03/201809/03/201829/03/2018-
07 Dec 2017InterimUSX1.0030/03/201730/09/201714/12/201715/12/201731/01/2018-
21 Sep 2017InterimUSX1.0002/03/201730/06/201728/09/201729/09/201731/10/2017-

Biopharma Credit Fundamentals

 31 Dec 2017 (GBP)31 Dec 2018 (GBP)31 Dec 2019 (GBP)31 Dec 2020 (USD)
pre tax profit29.8580.68%69.9572.35%113.8279.97%79.6780.10%m
attributable profit29.8580.68%69.9572.35%113.8279.97%79.6780.10%m
retained profit22.2360.09%-4.09-4.23%15.2110.68%-34.22-34.40%m
eps - basic3.89 7.07 8.28 5.80 
eps - diluted3.89 7.07 8.28 5.80 
dividends per share- - - - 

Biopharma Credit Balance Sheet

 31 Dec 2017 (GBP)31 Dec 2018 (GBP)31 Dec 2019 (GBP)31 Dec 2020 (USD)
 31 Dec 2017 (GBP)31 Dec 2018 (GBP)31 Dec 2019 (GBP)31 Dec 2020 (USD)
fixed assets fixed assets--%--%--%--%m
intangibles intangibles--%--%--%--%m
fixed investments fixed investments569.6361.55%1,007.2772.29%1,116.1378.11%1,194.8386.06%m
current assets - other current assets - other--%--%--%--%m
stocks stocks--%--%--%--%m
debtors debtors5.040.54%22.441.61%16.211.13%0.210.01%m
cash & securities cash & securities350.8237.91%363.5726.09%296.6420.76%193.2713.92%m
creditors - short creditors - short2.920.32%5.460.39%24.501.71%9.390.68%m
creditors - long creditors - long--%7.790.56%0.730.05%--%m
creditors - other creditors - other--%--%--%--%m
subordinated loans subordinated loans--%--%--%--%m
insurance funds insurance funds--%--%--%--%m
ord cap, reserves ord cap, reserves922.5799.68%1,380.0299.05%1,403.7498.23%1,378.9199.32%m
prefs, minorities prefs, minorities--%--%--%--%m
NAV Basic100.91 100.44 102.17 100.37 
NAV Diluted100.91 100.44 102.17 100.37 

Biopharma Credit Cash Flow Statement

31 Dec 2017 (GBP)31 Dec 2018 (GBP)31 Dec 2019 (GBP)31 Dec 2020 (USD)
Operating CF26.9167.14131.5258.07m
Pre-Financing CF-386.96-369.8531.2310.60m
Retained CF350.7712.79-66.92-103.36m

Biopharma Credit Brokers

Broker infomation is not available for this class of stock.
ADVFN Advertorial
Your Recent History
Biopharma ..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

Log in to ADVFN
Register Now
NYSE, AMEX, and ASX quotes are delayed by at least 20 minutes.
All other quotes are delayed by at least 15 minutes unless otherwise stated.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V:gb D:20220926 10:16:37